Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4166 in Type 2 Diabetes
NCT02524782Phase 1Completed
- Sponsor
- MedImmune
- Start
- Oct 2015
- Primary completion
- Apr 2017
- Modality
- Peptides, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing MEDI-4166 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events as a measure of safety and tolerability, Change in glucose AUC measured up to 240 minutes after mixed meal tolerance test (MMTT) and 1 more. Started Oct 2015; status: completed.
02
Drugs
MEDI4166
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02524782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524782.